Literature DB >> 12271474

Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen.

H Michael Tucker1, Muthoni Kihiko-Ehmann, Steven Estus.   

Abstract

Amyloid-beta (Abeta) appears central to Alzheimer's disease (AD), aggregates spontaneously, and is neurotoxic to neurons in vitro. Recently, several groups reported a familial AD locus on chromosome 10. Here, we note that urokinase-type plasminogen activator (uPA) is located within this locus. Previously, we reported that uPA and its functional homolog, tissue-type plasminogen activator, are induced by Abeta treatment of neurons in vitro as well as in a mouse model of Abeta accumulation in vivo. Moreover, the target of plasminogen activators, plasmin, degraded nonaggregated and aggregated Abeta and modulated Abeta toxicity and deposition. Here, we have evaluated the effects of uPA and plasminogen on Abeta fibril formation and neurotoxicity. We report that the combination of uPA and plasminogen, but neither alone, inhibits Abeta toxicity, reduces Abeta deposition in vitro, and inhibits Abeta fibrillogenesis. We interpret these observations as suggesting that uPA represents a possible candidate gene for the chromosome 10 familial AD locus. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12271474     DOI: 10.1002/jnr.10417

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  13 in total

1.  Specific amyloid β clearance by a catalytic antibody construct.

Authors:  Stephanie A Planque; Yasuhiro Nishiyama; Sari Sonoda; Yan Lin; Hiroaki Taguchi; Mariko Hara; Steven Kolodziej; Yukie Mitsuda; Veronica Gonzalez; Hameetha B R Sait; Ken-ichiro Fukuchi; Richard J Massey; Robert P Friedland; Brian O'Nuallain; Einar M Sigurdsson; Sudhir Paul
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 2.  Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.

Authors:  J Steven Jacobsen; Peter Reinhart; Menelas N Pangalos
Journal:  NeuroRx       Date:  2005-10

3.  Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds.

Authors:  Hiroaki Taguchi; Stephanie Planque; Gopal Sapparapu; Stephane Boivin; Mariko Hara; Yasuhiro Nishiyama; Sudhir Paul
Journal:  J Biol Chem       Date:  2008-10-30       Impact factor: 5.157

4.  Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications.

Authors:  Jinghong Kou; Junling Yang; Jeong-Eun Lim; Abhinandan Pattanayak; Min Song; Stephanie Planque; Sudhir Paul; Ken-Ichiro Fukuchi
Journal:  Mol Neurobiol       Date:  2014-04-15       Impact factor: 5.590

Review 5.  Plasminogen Activators in Neurovascular and Neurodegenerative Disorders.

Authors:  Manuel Yepes; Yena Woo; Cynthia Martin-Jimenez
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

6.  beta-Amyloid degradation and Alzheimer's disease.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  J Biomed Biotechnol       Date:  2006

Review 7.  β-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease.

Authors:  Xiaojuan Sun; Wei-Dong Chen; Yan-Dong Wang
Journal:  Front Pharmacol       Date:  2015-09-30       Impact factor: 5.810

8.  Activators and inhibitors of the plasminogen system in Alzheimer's disease.

Authors:  Rachel Barker; Patrick G Kehoe; Seth Love
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

9.  Genetic association of urokinase-type plasminogen activator gene rs2227564 site polymorphism with sporadic Alzheimer's disease in the Han Chinese population.

Authors:  Xuelian Ji; Longfei Jia; Jianping Jia; Li Qi
Journal:  Neural Regen Res       Date:  2012-10-25       Impact factor: 5.135

10.  Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease.

Authors:  Christopher D Whelan; Niklas Mattsson; Michael W Nagle; Swetha Vijayaraghavan; Craig Hyde; Shorena Janelidze; Erik Stomrud; Julie Lee; Lori Fitz; Tarek A Samad; Gayathri Ramaswamy; Richard A Margolin; Anders Malarstig; Oskar Hansson
Journal:  Acta Neuropathol Commun       Date:  2019-11-06       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.